Survey uncovers lupus corticosteroid treatment issuesPatients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
GSK Issues Voluntary Recall
GSK Issues Voluntary RecallNearly 600,000 inhalers are being recalled.
[BLOG] Pipeline advancement responsible for upturn in global pharma R&DThe world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.
Big Pharma activity heats upThe increase in recent acquisition activity among Big Pharma illustrates different growth strategies, according to industry watchers.
FDA approves Arzerra in combination with chlorambucil for patients with CLL for whom fludarabine-based therapy is considered inappropriateFDA has approved a new indication for ofatumumab (Arzerra, GlaxoSmithKline and Genmab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
FDA drug approvals: January 2014FDA approvals, complete response, fast-track designations, priority review, first-time generic approval
QIV found highly effective against moderate-to-severe flu, NEJM report says
QIV found highly effective against moderate-to-severe flu, NEJM report says
FDA lifts some restrictions on diabetes drug AvandiaFDA has eased restrictions on patient access to the controversial diabetes drug rosiglitazone (Avandia, GlaxoSmithKline). The agency made its determination after an FDA Advisory Committee reviewed the drug in June 2013 and voted to lift its restrictions, and new information was released indicating that the drug carries no heightened cardiovascular risk.
GSK, Community Care of North Carolina team to improve medication adherenceGlaxoSmithKline and Community Care North Carolina team up to put medication data to good use “What we found with small data is there are still a lot of barriers to being able to apply data,” says John Easter, senior director in the public policy department at GSK. “Providers may not have right data set or may be using legacy systems that can’t integrate with each other. What this group was able to do is create these models in a lightweight way so they only needed a small amount of data to predict the correct outcomes.”